C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells

(2016) Chi Hoon Park et al.   BMC CANCER

c-MET immunostaining in colorectal carcinoma is associated with local disease recurrence

(2015) Jaudah Al-Maghrabi et al.   BMC CANCER

Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model

(2015) Franziska Brandes et al.   BMC CANCER

Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients

(2015) Nozomu Fuse et al.   Gastric Cancer

Multimodal treatment of gastric cancer in the west: Where are we going?

(2015) Daniele Marrelli   WORLD JOURNAL OF GASTROENTEROLOGY

HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma

(2014) Y J Liu et al.   BRITISH JOURNAL OF CANCER

Abstract 3371: Preclinical disposition and pharmacokinetics of volitinib, a novel selective cMet inhibitor .

(2014) Yi Gu et al.   CANCER RESEARCH

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

(2014) E. Van Cutsem et al.   CLINICAL CANCER RESEARCH

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies

(2014) R. Salgia et al.   CLINICAL CANCER RESEARCH

Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress

(2014) Sharareh Gholamin et al.   CURRENT DRUG TARGETS

Synergistic Activity of the c-Met and Tubulin Inhibitor Tivantinib (ARQ197) with Pemetrexed in Mesothelioma Cells

(2014) Leticia Leon et al.   CURRENT DRUG TARGETS

MET As a Potential Target for the Treatment of Upper Gastrointestinal Cancers: Characterization of Novel c-Met Inhibitors from Bench to Bedside

(2014) A. Avan et al.   CURRENT MEDICINAL CHEMISTRY

Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in oesophageal adenocarcinoma but not in squamous cell carcinoma

(2014) Ildiko Mesteri et al.   EUROPEAN JOURNAL OF CANCER

Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study

(2014) Timothy Iveson et al.   LANCET ONCOLOGY

Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models

(2014) Paul R. Gavine et al.   Molecular Oncology

Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines

(2014) Antonio Calles et al.   Molecular Oncology

c-Met signaling in the development of tumorigenesis and chemoresistance: Potential applications in pancreatic cancer

(2014) Daniel Delitto   WORLD JOURNAL OF GASTROENTEROLOGY

The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models

(2014) Friedhelm Bladt et al.   Cancers

A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis

(2013) A Santoro et al.   BRITISH JOURNAL OF CANCER

Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma

(2013) A. Avan et al.   CANCER RESEARCH

EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors

(2013) F. Bladt et al.   CLINICAL CANCER RESEARCH

Targeting the MET gene for the treatment of non-small-cell lung cancer

(2013) F. Gelsomino et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

(2013) Yoon-Koo Kang et al.   INVESTIGATIONAL NEW DRUGS

Hepatocellular Carcinoma

(2013) Kisha A. Mitchell   JOURNAL OF CLINICAL GASTROENTEROLOGY

MET As a Possible Target for Non–Small-Cell Lung Cancer

(2013) Ahad A. Sadiq et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

(2013) Manish A. Shah et al.   PLoS One

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

(2013) M. Merchant et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Lentivirus-mediated RNA silencing of c-Met markedly suppresses peritoneal dissemination of gastric cancer in vitro and in vivo

(2012) Xiao-lei Wang et al.   ACTA PHARMACOLOGICA SINICA

Cellular and molecular mechanisms of hepatocellular carcinoma: an update

(2012) Rajagopal N. Aravalli et al.   ARCHIVES OF TOXICOLOGY

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome

(2012) H E Lee et al.   BRITISH JOURNAL OF CANCER

Abstract 3612: A novel and selective c-Met inhibitor against subcutaneous xenograft and othotopic brain tumor models

(2012) Yumin Cui et al.   CANCER RESEARCH

Met Kinase Inhibitor E7050 Reverses Three Different Mechanisms of Hepatocyte Growth Factor-Induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer

(2012) W. Wang et al.   CLINICAL CANCER RESEARCH

Enhancement of the Antiproliferative Activity of Gemcitabine by Modulation of c-Met Pathway in Pancreatic Cancer

(2012) Amir Avan et al.   CURRENT PHARMACEUTICAL DESIGN

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer

(2012) Elena Galvani et al.   CURRENT PHARMACEUTICAL DESIGN

Loss of HGF/c-Met Signaling in Pancreatic β-Cells Leads to Incomplete Maternal β-Cell Adaptation and Gestational Diabetes Mellitus

(2012) Cem Demirci et al.   DIABETES

Hepatocyte Growth Factor Plays a Key Role in Insulin Resistance-Associated Compensatory Mechanisms

(2012) Tiago G. Araújo et al.   ENDOCRINOLOGY

Response to Crizotinib inROS1-Rearranged Non–Small-Cell Lung Cancer

(2012) Takefumi Komiya et al.   JOURNAL OF CLINICAL ONCOLOGY

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

(2012) Armando Santoro et al.   LANCET ONCOLOGY

MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells

(2012) C.-T. Chen et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) in Gastric Cancer Positive for MET Amplification

(2012) W. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

(2012) Alex Kentsis et al.   NATURE MEDICINE

Microenvironment Elements Involved in the Development of Pancreatic Cancer Tumor

(2012) Katarzyna Gardian et al.   Gastroenterology Research and Practice

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

Multiple Mutations and Bypass Mechanisms Can Contribute to Development of Acquired Resistance to MET Inhibitors

(2011) J. Qi et al.   CANCER RESEARCH

c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target

(2011) Chenwei Li et al.   GASTROENTEROLOGY

Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197

(2011) Sudharshan Eathiraj et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Genetic Activation of theMETPathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer

(2011) Francesco Graziano et al.   JOURNAL OF CLINICAL ONCOLOGY

METAmplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib

(2011) Jochen K. Lennerz et al.   JOURNAL OF CLINICAL ONCOLOGY

665 A PHASE I/II STUDY OF FORETINIB, AN ORAL MULTIKINASE INHIBITOR TARGETING MET, RON, AXL, TIE-2 AND VEGFR IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

(2011) T. Yau et al.   JOURNAL OF HEPATOLOGY

Induction of MET by Ionizing Radiation and Its Role in Radioresistance and Invasive Growth of Cancer

(2011) Francesca De Bacco et al.   JNCI-Journal of the National Cancer Institute

Activity of Crizotinib (PF02341066), a Dual Mesenchymal-Epithelial Transition (MET) and Anaplastic Lymphoma Kinase (ALK) Inhibitor, in a Non-small Cell Lung Cancer Patient with De Novo MET Amplification

(2011) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

HCC and angiogenesis: possible targets and future directions

(2011) Andrew X. Zhu et al.   Nature Reviews Clinical Oncology

Hepatocellular Carcinoma

(2011) Hashem B. El-Serag   NEW ENGLAND JOURNAL OF MEDICINE

Silencing of RON Receptor Signaling Promotes Apoptosis and Gemcitabine Sensitivity in Pancreatic Cancers

(2010) J. Logan-Collins et al.   CANCER RESEARCH

MET and KRAS Gene Amplification Mediates Acquired Resistance to MET Tyrosine Kinase Inhibitors

(2010) V. Cepero et al.   CANCER RESEARCH

Disruption of Hepatocyte Growth Factor/c-Met Signaling Enhances Pancreatic  -Cell Death and Accelerates the Onset of Diabetes

(2010) J. Mellado-Gil et al.   DIABETES

Expression and Prognostic Significance of CD151, c-Met, and Integrin alpha3/alpha6 in Pancreatic Ductal Adenocarcinoma

(2010) Guang-Hui Zhu et al.   DIGESTIVE DISEASES AND SCIENCES

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

(2010) Yung-Jue Bang et al.   LANCET

TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non-Small Cell Lung Cancer with an EGFR Mutation

(2010) W. Okamoto et al.   MOLECULAR CANCER THERAPEUTICS

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Descriptive epidemiology of cholangiocarcinoma in Italy

(2009) Domenico Alvaro et al.   DIGESTIVE AND LIVER DISEASE

PAX6 Is Expressed in Pancreatic Cancer and Actively Participates in Cancer Progression through Activation of the MET Tyrosine Kinase Receptor Gene

(2009) Joseph B. Mascarenhas et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma

(2009) C.-F. Gao et al.   MOLECULAR CANCER THERAPEUTICS

Developing c-MET pathway inhibitors for cancer therapy: progress and challenges

(2009) Xiangdong Liu et al.   TRENDS IN MOLECULAR MEDICINE

The Met tyrosine kinase receptor in development and cancer

(2008) Alessandra Gentile et al.   CANCER AND METASTASIS REVIEWS

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

(2008) Zhao-Shi Zeng et al.   CANCER LETTERS

MET receptor tyrosine kinase as a therapeutic anticancer target

(2008) Christine M. Stellrecht et al.   CANCER LETTERS

MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

(2008) H. Jin et al.   CANCER RESEARCH

The Prognostic Significance of RON and MET Receptor Coexpression in Patients with Colorectal Cancer

(2008) Chung-Ta Lee et al.   DISEASES OF THE COLON & RECTUM

Expression and mutational analysis ofMETin human solid cancers

(2008) Patrick C. Ma et al.   GENES CHROMOSOMES & CANCER

Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma

(2008) Ai-Wu Ke et al.   HEPATOLOGY

Drug development of MET inhibitors: targeting oncogene addiction and expedience

(2008) Paolo M. Comoglio et al.   NATURE REVIEWS DRUG DISCOVERY